Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Cysteamine as a topical management option for melasma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Hira SK;Hira SK; Nalluri R; Nalluri R
  • المصدر:
    Clinical and experimental dermatology [Clin Exp Dermatol] 2022 Mar; Vol. 47 (3), pp. 646-647. Date of Electronic Publication: 2021 Nov 23.
  • نوع النشر :
    Journal Article
  • اللغة:
    English
  • معلومة اضافية
    • المصدر:
      Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2230 (Electronic) Linking ISSN: 03076938 NLM ISO Abbreviation: Clin Exp Dermatol Subsets: MEDLINE
    • بيانات النشر:
      Publication: 2023- : Oxford : Oxford University Press
      Original Publication: Oxford : Blackwell Scientific Publications.
    • الموضوع:
      Cysteamine/*administration & dosage ; Dermatologic Agents/*administration & dosage ; Melanosis/*drug therapy; Administration, Topical ; Humans ; Intention to Treat Analysis ; Skin Cream ; Treatment Outcome
    • References:
      Nguyen J, Remyn L, Chung I et al. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: a randomised, double-blinded trial. Australas J Dermatol 2020; 62: e41-6.
      Rajanala S, Maymone M, Vashi N. Melasma pathogenesis: a review of the latest research, pathological findings, and investigational therapies. Dermatol Online J 2019; 25: 13030/qt47b7r28c.
      Qiu L, Zhang M, Tonks I et al. Inhibition of melanin synthesis by cystamine in human melanoma cells. J Invest Dermatol 2000; 114: 21-7.
      Jeitner T, Pinto J, Cooper A. Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo. Biosci Rep 2018; 38: BSR20180691.
      Atallah C, Charcosset C, Greige-Gerges H. Challenges for cysteamine stabilization, quantification, and biological effects improvement. J Pharm Anal 2020; 10: 499-516.
    • الرقم المعرف:
      0 (Dermatologic Agents)
      5UX2SD1KE2 (Cysteamine)
    • الموضوع:
      Date Created: 20211124 Date Completed: 20220309 Latest Revision: 20220309
    • الموضوع:
      20240829
    • الرقم المعرف:
      10.1111/ced.14958
    • الرقم المعرف:
      34816461